Revolutionizing healthcare with exosomes focusing on gastrointestinal, liver and kidney regeneration

EverZom is an exosome biotech company developing treatments for digestive tissue healing like Crohn's fistula and organ regeneration like the kidney and the liver.

Founded in 2019, EverZom is positioned to become the leader of exosome therapeutics, the next wave of innovation for the biotech industry. Exosomes, small vesicles secreted by cells, are increasingly recognized as potent agents for intercellular communication and play a crucial role to treat a wide range of diseases. Winner of the European EIC Accelerator Program, EVerZom aims to be the upcoming pioneer in this new field.

The company has successfully developed a multi-patented platform which enables exosome sourcing, generation, loading, and formulation to create proprietary programs and establish early-stage partnerships in the field of regenerative therapy and oncology.